Scientists at Institut Pasteur have gained new insights into how some people control HIV-1 replication after interruption of antiretroviral treatment (ART). The investigators found a fingerprint involved in long-term viral remission. Read More
SMARCA4 and SMARCA2 are essential subunits of the SWI/SNF complex, functioning as ATP-dependent chromatin remodelers that regulate gene expression and maintain cellular homeostasis. Recent research has shown that selectively targeting SMARCA2 is an effective cancer treatment strategy, with several compounds already in early clinical testing. Read More
The National Institutes of Health (NIH) is adopting a new initiative to expand innovative, human-based science while reducing animal use in research. Developing and using alternative nonanimal research models aligns with the FDA’s recent initiative to reduce testing in animals. Read More
The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the uncertainty, BioWorld continues to cover the administration’s latest policy decisions and actions affecting the life sciences sector, as well as their impacts across the globe. It’s all right here at Trump administration impacts. Read More
BioWorld is pleased to begin providing a new quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter. NMEs include compounds chosen for further pharmacological evaluation or as clinical candidates; new leads whose structural optimization could provide new therapeutic agents; new additions to the structural diversity of known mechanistic classes of drugs; and new pharmacological tools for investigating drug targets. Read More
Creyon Bio Inc. has entered into a global licensing and multitarget research collaboration with Eli Lilly & Co. focused on the discovery, development and commercialization of novel RNA-targeted oligonucleotide therapies for a broad range of diseases. Read More
Anticoagulant drugs, whether classical ones such as warfarin and heparin or newer ones such as dabigatran and apixaban, can be effective for treating and preventing deep vein thrombosis, myocardial infarction, ischemic stroke and pulmonary embolisms. Targeting factor XIa, a serine protease in the coagulation pathway, may inhibit thrombosis without increasing bleeding risk. Numerous inhibitors of factor XIa have been developed and several have entered clinical trials, but most have shown problems of poor efficacy, inadequate selectivity or drug-drug interactions. Read More
Unravel Biosciences Inc. has submitted clinical study applications in Colombia seeking to begin proof-of-concept clinical trials for RVL-001 for Rett syndrome and Pitt-Hopkins syndrome. Read More
Blueprint Medicines Corp. has disclosed EGFR mutant inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC). Read More
Multiple myeloma (MM) is a complex disease with poor prognosis and its clinical management still remains a challenge in the field. Since both BCMA and GPRC5D are overexpressed in MM cells, a therapeutic approach targeting both would be of interest. Qilu Pharmaceutical Co. Ltd. is hence developing a dual BCMA- and GPRC5D-targeting antibody – QLS-4131 – for the treatment of MM. Read More
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified relaxin receptor 1 (RXFP1; LGR7) agonists reported to be useful for the treatment of heart failure, chronic kidney disease, acute kidney injury, fibrosis and inflammatory disorders. Read More
Alphina Therapeutics Inc. has described nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors reported to be useful for the treatment of cancer, and autoimmune, inflammatory and metabolic disorders. Read More
Abnormal fusion of the FGFR2 gene, encoding the fibroblast growth factor receptor 2, occurs in several types of cancer, including in up to 15% of cases of intrahepatic cholangiocarcinoma. Read More
